博纳吐单抗-话题@MedSci

#博纳吐单抗#

8篇内容 | 935人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1344602, encodeId=6e7d1344602a1, content=<a href='/topic/show?id=f59c3646245' target=_blank style='color:#2F92EE;'>#博纳吐单抗#</a>, objectTitle=J Clin Oncol：博纳吐单抗诱导巩固+POMP维持治疗Ph染色体阴性B-ALL老年患者的疗效, objectType=article, longId=299130, objectId=317729913045, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=317729913045, replyNumber=0, likeNumber=29, createdTime=2022-02-20, rootId=0, userName=ms9203727104890838, userId=706e2500208, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=317729913045, moduleTitle=J Clin Oncol：博纳吐单抗诱导巩固+POMP维持治疗Ph染色体阴性B-ALL老年患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=317729913045)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344601, encodeId=5a29134460135, content=<a href='/topic/show?id=f59c3646245' target=_blank style='color:#2F92EE;'>#博纳吐单抗#</a>, objectTitle=J Clin Oncol：博纳吐单抗无反应和高疾病负荷提示，B-ALL患者采用CD19-CAR治疗的预后不良, objectType=article, longId=220543, objectId=20ce220543ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20ce220543ab, replyNumber=0, likeNumber=37, createdTime=2021-11-19, rootId=0, userName=ms9203727104890838, userId=706e2500208, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20ce220543ab, moduleTitle=J Clin Oncol：博纳吐单抗无反应和高疾病负荷提示，B-ALL患者采用CD19-CAR治疗的预后不良, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20ce220543ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344600, encodeId=b32913446007f, content=<a href='/topic/show?id=f59c3646245' target=_blank style='color:#2F92EE;'>#博纳吐单抗#</a>, objectTitle=Eur J Cancer：复发/难治性费城染色体阳性ALL患者采用博纳吐单抗治疗的长期疗效, objectType=article, longId=207387, objectId=dc5120e387fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc5120e387fe, replyNumber=0, likeNumber=32, createdTime=2021-02-22, rootId=0, userName=ms9203727104890838, userId=706e2500208, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc5120e387fe, moduleTitle=Eur J Cancer：复发/难治性费城染色体阳性ALL患者采用博纳吐单抗治疗的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc5120e387fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344599, encodeId=ef6a1344599a3, content=<a href='/topic/show?id=f59c3646245' target=_blank style='color:#2F92EE;'>#博纳吐单抗#</a>, objectTitle=达沙替尼-博纳吐单抗治疗成人ph+急性淋巴细胞白血病, objectType=article, longId=202422, objectId=f58020242298, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f58020242298, replyNumber=0, likeNumber=35, createdTime=2020-10-25, rootId=0, userName=ms9203727104890838, userId=706e2500208, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f58020242298, moduleTitle=达沙替尼-博纳吐单抗治疗成人ph+急性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f58020242298)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344598, encodeId=ed301344598a0, content=<a href='/topic/show?id=f59c3646245' target=_blank style='color:#2F92EE;'>#博纳吐单抗#</a>, objectTitle=NEJM：达沙替尼-博纳吐单抗治疗费城染色体阳性急性淋巴细胞白血病, objectType=article, longId=202407, objectId=564a20240ecb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=564a20240ecb, replyNumber=0, likeNumber=33, createdTime=2020-10-24, rootId=0, userName=ms9203727104890838, userId=706e2500208, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=564a20240ecb, moduleTitle=NEJM：达沙替尼-博纳吐单抗治疗费城染色体阳性急性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=564a20240ecb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344597, encodeId=d79e134459e1e, content=<a href='/topic/show?id=f59c3646245' target=_blank style='color:#2F92EE;'>#博纳吐单抗#</a>, objectTitle=Blood：影响B-ALL患者博纳吐单抗治疗效果的肿瘤内外标志物, objectType=article, longId=200711, objectId=6fc9200e1160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fc9200e1160, replyNumber=0, likeNumber=38, createdTime=2020-09-17, rootId=0, userName=ms9203727104890838, userId=706e2500208, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fc9200e1160, moduleTitle=Blood：影响B-ALL患者博纳吐单抗治疗效果的肿瘤内外标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fc9200e1160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344596, encodeId=d4d4134459655, content=<a href='/topic/show?id=f59c3646245' target=_blank style='color:#2F92EE;'>#博纳吐单抗#</a>, objectTitle=Blood：博纳吐单抗用于复发性/难治性急性淋巴细胞白血病成年患者不仅可延长其存活期，还可改善其生活质量, objectType=article, longId=137632, objectId=d12113e632d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d12113e632d1, replyNumber=0, likeNumber=47, createdTime=2018-05-11, rootId=0, userName=ms9203727104890838, userId=706e2500208, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d12113e632d1, moduleTitle=Blood：博纳吐单抗用于复发性/难治性急性淋巴细胞白血病成年患者不仅可延长其存活期，还可改善其生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d12113e632d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344595, encodeId=66e9134459592, content=<a href='/topic/show?id=f59c3646245' target=_blank style='color:#2F92EE;'>#博纳吐单抗#</a>, objectTitle=Blood：博纳吐单抗用于最小残留病灶阳性的B前体急性淋巴细胞白血病患者的效果和安全性, objectType=article, longId=127995, objectId=195b12e99577, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=195b12e99577, replyNumber=0, likeNumber=26, createdTime=2018-01-29, rootId=0, userName=ms9203727104890838, userId=706e2500208, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=195b12e99577, moduleTitle=Blood：博纳吐单抗用于最小残留病灶阳性的B前体急性淋巴细胞白血病患者的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=195b12e99577)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

博纳吐单抗

2020-05-29

ms9203727104890838 (审核中...)

前往app查看评论内容

#博纳吐单抗#

J Clin Oncol：博纳吐单抗诱导巩固+POMP维持治疗Ph染色体阴性B-ALL老年患者的疗效

2022-02-20

ms9203727104890838 (审核中...)

前往app查看评论内容

#博纳吐单抗#

J Clin Oncol：博纳吐单抗无反应和高疾病负荷提示，B-ALL患者采用CD19-CAR治疗的预后不良

2021-11-19

ms9203727104890838 (审核中...)

前往app查看评论内容

#博纳吐单抗#

Eur J Cancer：复发/难治性费城染色体阳性ALL患者采用博纳吐单抗治疗的长期疗效

2021-02-22

ms9203727104890838 (审核中...)

前往app查看评论内容

#博纳吐单抗#

达沙替尼-博纳吐单抗治疗成人ph+急性淋巴细胞白血病

2020-10-25

ms9203727104890838 (审核中...)

前往app查看评论内容

#博纳吐单抗#

NEJM：达沙替尼-博纳吐单抗治疗费城染色体阳性急性淋巴细胞白血病

2020-10-24

ms9203727104890838 (审核中...)

前往app查看评论内容

#博纳吐单抗#

Blood：影响B-ALL患者博纳吐单抗治疗效果的肿瘤内外标志物

2020-09-17

ms9203727104890838 (审核中...)

前往app查看评论内容

#博纳吐单抗#

Blood：博纳吐单抗用于复发性/难治性急性淋巴细胞白血病成年患者不仅可延长其存活期，还可改善其生活质量

2018-05-11

ms9203727104890838 (审核中...)

前往app查看评论内容

#博纳吐单抗#

Blood：博纳吐单抗用于最小残留病灶阳性的B前体急性淋巴细胞白血病患者的效果和安全性

2018-01-29

科室
- - 订阅+
  - 更多科室
工具
服务